Several studies have shown that microspheres may have a dual role: They may be used to enhance the effect of sonothrombolysis and assist in targeted drug delivery. To date, transcranial US has mainly been developed for diagnostic purposes. Several experimental studies have been

conducted or are being undertaken to optimize US settings for sonothrombolysis. A need still exists to determine the optimal US frequency and energy so as to achieve the safest and most effective form of US for Forskolin cost sonothrombolysis. “
“Intravenous tissue plasminogen activator (tPA) remains the only approved therapy for acute ischemic stroke [1] that can be administered fast and at any level emergency room equipped with a non-contrast CT scanner. Even though patients with severe strokes and proximal arterial occlusions are less likely to respond to tPA, they still do better than

Gefitinib in vitro placebo-treated patients [1]. The presence of a proximal arterial occlusion should not be viewed as an insurmountable predictor of tPA failure since nutritious recanalization can occur even with large middle cerebral (MCA) or internal carotid artery (ICA) thrombi [2] and [3]. Even if intra-arterial interventions are approved in the future for stroke treatment, it is unrealistic to expect that all patients with MCA occlusions either will reach comprehensive stroke centers in time or their risk factor profile would always make catheter intervention feasible. With bridging intravenous–intra-arterial protocols being tested, there is even further need to amplify the systemic part of reperfusion therapy so that more patients could benefit from early treatment initiation [4]. Early clinical improvement after stroke usually occurs after arterial recanalization [5], [6], [7] and [8]. The so-called “recanalization hypothesis” links the occurrence of recanalization with increase of good functional outcome and reduction of death [9], however this hypothesis has not been confirmed in a prospective clinical trial, subject of an ongoing CLOTBUST-PRO multi-center study

[10]. In the CLOTBUST trial [11], early recanalization coupled with early dramatic recovery Urease was more common among tPA treated patients who were exposed to continuous vs intermittent monitoring with pulsed wave 2 MHz TCD (25% vs 8%). This, in turn, produced a trend towards more patients recovering at 3 months to modified Ranking score 0–1 (42% vs 29%) [11]. Diagnosis of an acute intracranial occlusion, re-canalization and re-occlusion in the CLOTBUST trial was based on the thrombolysis in brain ischemia (TIBI) residual flow grading system [12]. It describes typical waveforms that identify residual flow around an arterial occlusion, and their detailed definitions were published elsewhere [13].